Business Context and Reporting Period
Aprea Therapeutics, Inc. (APRE) is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The company is reporting for the quarterly period ended June 30, 2024. Its primary clinical programs are ATRN-119, an oral ATR inhibitor, and APR-1051, an oral WEE1 kinase inhibitor. The company has no commercial product sales and relies on grants and equity financing.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2024 | As of June 30, 2024 |
|---|---|---|---|
| Grant Revenue | $561,574 | $942,143 | N/A |
| Net Loss | $(3,470,052) | $(6,280,143) | N/A |
| Loss Per Share (Basic & Diluted) | $(0.58) | $(1.24) | N/A |
| Research & Development Expenses | $2,557,679 | $4,158,052 | N/A |
| General & Administrative Expenses | $1,850,819 | $3,780,685 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $28,694,694 |
| Total Assets | N/A | N/A | $29,964,587 |
| Accumulated Deficit | N/A | N/A | $(314,363,304) |
Material Changes vs. Prior Period
- Revenue: Grant revenue increased significantly to $0.94 million for the six months ended June 30, 2024, compared to $0.25 million in the same period in 2023, primarily due to funding from the National Cancer Institute.
- Net Loss: The net loss improved to $6.28 million for the six months ended June 30, 2024, compared to $7.64 million in the prior year period.
- Operating Expenses:
- R&D: Increased by $0.70 million year-over-year for the six-month period, driven by the initiation of the Phase 1 dose-escalation study for APR-1051.
- G&A: Decreased by $1.28 million year-over-year for the six-month period, primarily due to a reduction in personnel costs related to severance expenses for former executives.
- Liquidity: Cash and cash equivalents increased from $21.6 million at December 31, 2023, to $28.7 million at June 30, 2024, following a private placement in March 2024.
Guidance, Outlook, and Risks
- Clinical Outlook:
- ATRN-119: The Phase 1/2a trial (ABOYA-119) is ongoing. The first five dose cohorts are complete. Management anticipates Phase 1 readout in the first half of 2025.
- APR-1051: The FDA cleared the IND in March 2024, and the first patient was enrolled in the ACESOT-1051 Phase 1 study in Q2 2024. An update is expected by year-end 2024, with open-label safety/efficacy data expected in the first half of 2025.
- Liquidity Runway: Management believes the current cash balance of approximately $28.7 million is sufficient to fund operations into the fourth quarter of 2025.
- Financing: The company completed a private placement in March 2024 raising approximately $16.0 million in gross proceeds. An At-the-Market (ATM) agreement entered in January 2024 was terminated in March 2024 with no sales made.
- Risks:
- Significant dependence on the success of ATRN-119 and APR-1051, which are in early clinical stages.
- Need for substantial additional funding to continue operations beyond late 2025.
- Reliance on third-party manufacturers and CROs.
- Uncertainty regarding clinical trial outcomes and regulatory approvals.
Investor Verification Checklist
- Verify the specific milestones and timelines for the ATRN-119 and APR-1051 clinical trials against the stated expectations for 2025 readouts.
- Confirm the company's cash burn rate and the sufficiency of the $28.7 million cash balance to reach the projected Q4 2025 runway.
- Review the terms of the March 2024 private placement, specifically the exercise prices and conditions for the Tranche A and Tranche B warrants.
- Assess the impact of the terminated ATM agreement on future capital raising strategies.
- Monitor the status of the Phase 1 dose escalation for ATRN-119 and the enrollment progress for APR-1051.